Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

被引：8

作者：

Kuchnio, Anna ^{[1
]}

Samakai, Elsie ^{[2
]}

Hug, Eva ^{[3
]}

Balmana, Meritxell ^{[3
]}

Janssen, Lut ^{[1
]}

Amorim, Ricardo ^{[1
]}

Cornelissen, Ivo ^{[1
]}

Majoros, Andrea ^{[3
]}

Broux, Michael ^{[1
]}

Taneja, Isha ^{[2
]}

Torti, Vince ^{[4
]}

Agic, Azra ^{[3
]}

Moritsch, Stefan ^{[3
]}

Benedetti, Filippo ^{[3
]}

Rosebrock, Felix ^{[3
]}

Packman, Kathryn ^{[5
]}

Arts, Janine ^{[6
]}

Patel, Sonal ^{[7
]}

Lomas, Oliver Christopher ^{[8
]}

Deyoung, M. Phillip ^{[2
]}

Zagrijtschuk, Oleh ^{[3
]}

Elsayed, Yusri ^{[9
]}

Constantinescu, Stefan ^{[10
,11
,12
,13
]}

Kralovics, Robert ^{[14
]}

Philippar, Ulrike ^{[15
]}

机构：

[1] Janssen Res & Dev, Beerse, Belgium

[2] Janssen Res & Dev, Spring House, PA USA

[3] MyeloPro Diagnost & Res GmbH, Vienna, Austria

[4] Janssen Res & Dev, La Jolla, CA USA

[5] Janssen Res & Dev LLC, Cambridge, MA USA

[6] Janssen Sci Innovat Oncol, Beerse, Belgium

[7] Janssen Sci Innovat Oncol, London, England

[8] Janssen Res & Dev, High Wycombe, England

[9] Janssen Res & Dev LLC, Spring House, PA USA

[10] Ludwig Inst Canc Res, Brussels, Belgium

[11] UCLouvain, Duve Inst, Brussels, Belgium

[12] Wel Res Inst, Welbio Dept, Wavre, Belgium

[13] Univ Oxford, Nuffield Dept Med, Ludwig Canc Res Oxford, Oxford, England

[14] Med Univ Vienna, Vienna, Austria

[15] Janssen Res & Dev LLC, Beerse, Belgium

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173430

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 44 条

[21] A Novel T-Cell Redirecting Anti-CD19-F(ab)2/CD3scFv Bispecific Antibody Exhibits Potent Lymphoma Cytotoxicity
Rossi, Diane L.
Rossi, Edmund A.
Cardillo, Thomas M.
Goldenberg, David M.
Chang, Chien-Hsing
BLOOD, 2012, 120 (21)
[22] The First-In-Class Anti-AXLxCD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas
Polera, Nicoletta
Mancuso, Antonia
Riillo, Caterina
Caracciolo, Daniele
Signorelli, Stefania
Grillone, Katia
Ascrizzi, Serena
Hokanson, Craig A.
Conforti, Francesco
Staropoli, Nicoletta
Gervasi, Luigia
Di Martino, Maria Teresa
Arbitrio, Mariamena
Nistico, Giuseppe
Crea, Roberto
Tagliaferri, Pierosandro
Juli, Giada
Tassone, Pierfrancesco
CANCERS, 2023, 15 (06)
[23] First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.
Bagot, Martine
Duvic, Madeleine
Vermeer, Maarten
Porcu, Pierluigi
Whittaker, Sean
Ram-Wolff, Caroline
Paiva, Christine
Marie-Cardine, Anne
Bonnafous, Cecile
Paturel, Carine
Moriette, Frederique
Zerbib, Robert Albert
Bensussan, Armand
Sicard, Helene
Pilz, Korinna
Kim, Youn H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Paz-Ares, Luis
Champiat, Stephane
Lai, W. Victoria
Izumi, Hiroki
Govindan, Ramaswamy
Boyer, Michael
Hummel, Horst-Dieter
Borghaei, Hossein
Johnson, Melissa L.
Steeghs, Neeltje
Blackhall, Fiona
Dowlati, Afshin
Reguart, Noemi
Yoshida, Tatsuya
He, Kai
Gadgeel, Shirish M.
Felip, Enriqueta
Zhang, Yiran
Pati, Amrita
Minocha, Mukul
Mukherjee, Sujoy
Goldrick, Amanda
Nagorsen, Dirk
Sadraei, Nooshin Hashemi
Owonikoko, Taofeek K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 2893 - 2903
[25] Efficacy and preclinical safety of ARB202, a potential first-in-class anti-CDH17/CD3 bispecific T-cell engager, for treatment of pancreatic and colorectal cancers.
Wong, Dennis A.
Luk, Moon Ching
Wong, Tony K.
Staunton, Donald E.
Harlan, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[26] Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL
Stefano, Sammicheli
Grandclement, Camille
Labanca, Valentina
De Angelis, Stefania
Estoppey, Carole
Chimen, Myriam
Pouleau, Blandine
Suere, Perrine
Nallet, Emilie
Srivastava, Ankita
Feldman, Eric J.
Proscurshim, Igor
Konto, Cyril
Zhukovsky, Eugene
Perro, Mario
BLOOD, 2022, 140 : 6237 - 6238
[27] IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
Bagot, Martine
Porcu, Pierluigi
Marie-Cardine, Anne
Battistella, Maxime
William, Basem M.
Vermeer, Maarten
Whittaker, Sean
Rotolo, Federico
Ram-Wolff, Caroline
Khodadoust, Michael S.
Bensussan, Armand
Paturel, Carine
Bonnafous, Cecile
Sicard, Helene
Azim, Hatem A., Jr.
Kim, Youn H.
LANCET ONCOLOGY, 2019, 20 (08): : 1160 - 1170
[28] First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC
Peterlin, Pierre
Saada-Bouzid, Esma
Moskovitz, Mor
Pigneux, Arnaud
Yuda, Junichiro
Sinnollareddy, Mahipal
Henner, William R.
Chen, Diana
Freise, Kevin J.
Leibman, Rachel S.
Avigdor, Abraham
Shimizu, Toshio
EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (09) : 893 - 904
[29] Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia
Paulus, Geraldine
Lee, Benjamin
Sankaran, Preethi
Rahman, Tanzila
Jimenez, Jessica
O'Connor, Delainey
Yue, Simon
Huang, Yu
Bikowitz, Melissa
Jaffe, Sarah
O'Malley, Shawn
Ban, Bhupal
Gabriely, Galina
Wang, Tao
Mak, Amanda
Princiotta, Michael
Shi, Chunhua
He, Helen
Feng, Ningping
Yan, Jun
Heffernan, Timothy
Alatrash, Gheath
Molldrem, Jeffrey
Wiederschain, Dmitri
CANCER RESEARCH, 2024, 84 (06)
[30] A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Kumar, Shaji
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Bueno, Orlando F.
Ben Buelow
Freise, Kevin J.
Yue, Susan
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth R.
Vij, Ravi
BLOOD, 2021, 138

← 1 2 3 4 5 →